Semaglutide for Weight Loss in Non-Diabetics While semaglutide gained prominence as a T2D intervention, it has since gained recognition as a potent weight-loss agent in non-diabetics
Making Wegovy part of a once-weekly routine
Tendency of semaglutide to induce gastroparesis: A case report, Cureus (2024) Gastroparesis, StatPearls (2024) Highlights of prescribing information, Novo Nordisk (2023) Risk of gastrointestinal adverse effects associated with glucagon-like peptide-1 receptor agonist for weight loss, J ournal of the American Medical Association (2023) Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: A cross-sectional analysis of the National Institute of Health All of Us cohort, Pharmaceuticals (2024) Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonist: Potential relevance for bariatric and other gastric surgery, BJS Open (2023) Ozempic drug label, DailyMed (2023) Patients taking popular medications for diabetes and weight loss should stop before elective surgery, ASA suggests, American Society of Anesthesiologists (2023) Diabetic gastroparesis: A review, Diabetes Spectrum (2020) They took blockbuster drugs for weight loss and diabetes
Not registered in Medicaid or other state or federal health programs
The staff at BodEvolve Bariatrics provides all types of weight-loss solutions, ranging from medical weight management options to the life-altering bariatric surgery procedures that many Dallas-Fort Worth area individuals choose
